Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, explains ways artificial intelligence (AI) is being used in dermatology, including smartphone applications, at the 2022 American Academy of Dermatology Annual Meeting.
Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, highlights the ways artificial intelligence (AI) is being used in dermatology, including smartphone applications.
Transcript
How is AI being used in dermatology?
It's a super exciting time in dermatology and medicine, as artificial intelligence is really coming to the forefront of the way that we're going to practice medicine. Really, the bulk of the research has been on identification of melanoma from images, and there's been a number of papers since 2017 showing that artificial intelligence algorithms are as good or better than dermatologists at interpreting pigmented lesions. Also, this stands for other skin cancers and there's more and more research being published in that area. Even though it's in its infancy, there is more research now into inflammatory skin disease like acne, rosacea, eczema, and psoriasis, so it's a very exciting time. In Europe, there's a few apps and algorithms that now have CE mark, but in dermatology, nothing is yet FDA approved, so anything that's being done at the moment is very much experimental in research.
How are smartphone apps that use AI helping to diagnose and treat dermatological conditions?
I actually did some research recently on smartphone apps. We scoured the Apple App Store, Google Play Store, as well as Google desktop, and actually there's a huge amount of dermatology apps out there, but extremely unregulated. As I mentioned earlier, there's only really 3 that have a CE mark in Europe, whereas the rest are being sort of sold under the guise of being a research tool of education. It's really important that there's a lot more jurisdiction and regulation of the apps that are out there. Beyond skin cancer, there are some proprietary apps that look at acne and suggest topical treatments for acne. Quite interestingly, there are some apps and imaging software that will allow us to do PASI [Psoriasis Area and Severity Index] and EASI [Eczema Area and Severity Index] scoring, which will make it a much better, more objective method of scoring patients.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More